Study of 3HP-327 for advanced solid tumors with FGFR2 changes
Part of Cancer clinical trials.
This trial tests a new drug, 3HP-327, for people with advanced solid tumors that have certain changes in the FGFR2 gene and have not responded to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a solid tumor that is advanced or has spread and cannot be removed by surgery.
- Your tumor has a specific change in the FGFR2 gene (your doctor can test for this).
- You are generally in good health (able to do light activities) and expected to live at least 3 months.
- You have not had other cancers in the last 3 years, and any side effects from previous treatments have mostly gone away.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, 3HP-2827, for people with advanced solid tumors that have a specific change (alteration) in the FGFR2 gene. The goal is to see if the drug can shrink tumors or stop them from growing.
This Phase 2 study tests a treatment aimed at specific FGFR (a cancer-growth signal) changes found in your tumor. It may help people whose cancer has spread, cannot be removed, or has stopped responding to standard treatment.
This trial tests a new drug called SHR-3276 for people with advanced cancers that haven't responded to standard treatments. It aims to see if the drug is safe and works against tumors.
This study tests an experimental oral drug (CSCJC3456) that may target certain genetic changes (FGFR) in advanced cancers. It might be an option if your cancer has not improved with standard treatments.
This trial tests MPB-1734, a new study drug, in adults with advanced solid tumors that can’t be removed and for which standard treatment has stopped working. It aims to find out how safe it is and whether it can shrink or control the cancer.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Hear when a new Solid Tumors With FGFR2 Alterations, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.